* Kalvista Pharmaceuticals Inc KALV.OQ reported a
quarterly
adjusted loss of 87 cents per share for the quarter ended July
31, lower than the same quarter last year, when the company
reported EPS of -74 cents. The mean expectation of
five analysts for the quarter was for a loss of 91 cents per
share. Wall Street expected results to range from $-1.02 to -80
cents per share.
* Reported revenue was zero; analysts expected zero.
* Kalvista Pharmaceuticals Inc's reported EPS for the
quarter was
a loss of 87 cents.
* The company reported a quarterly loss of $40.44 million.
* Kalvista Pharmaceuticals Inc shares had risen by 9.7% this
quarter and gained 5.5% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 35.7%
in the last three months.
* In the last 30 days, one analyst negatively revised an
earnings
estimate
RECOMMENDATIONS
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the
pharmaceuticals
peer group is "buy."
Wall Street's median 12-month price target for Kalvista
Pharmaceuticals Inc is $32.00
This summary was machine generated from LSEG data September 5 at
01:31 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jul. 31 2024 -0.91 -0.87 Beat
Apr. 30 2024 -0.73 -1.02 Missed
Jan. 31 2024 -0.77 -0.84 Missed
Oct. 31 2023 -0.79 -0.80 Missed